Rhode Island Cannabis: 8 Stores, $5.67 Flower, 39% Capture, and the Monopoly Feeding Massachusetts

Rhode Island's cannabis market generates $120 million in annual sales through just eight dispensaries — the second most under-licensed market in the country behind Virginia. With 60% of demand going to Massachusetts border dispensaries and the illicit market, the state's incumbents are lobbying to block new competition while cultivators go bankrupt and consumers drive 15 minutes to cheaper product across the state line.

The Numbers

Rhode Island legalized adult-use cannabis in May 2022 under the Rhode Island Cannabis Act, with sales beginning in December 2022 through existing medical compassion centers converted to hybrid licenses. The market operates under the Cannabis Control Commission (CCC), with seed-to-sale tracking through Metrc.

As of February 2026, eight dispensaries serve the entire state. That's it. Eight stores for 830,000 adults 21 and older — a density of 0.96 per 100,000, the second-lowest in the country behind Virginia's 0.3. Despite this, the state generated $120.1 million in retail sales in 2025, up slightly from $118 million in 2024.

The per-store numbers tell the real story: $15.0 million annualized per dispensary — the highest in the nation by a wide margin. Maryland's $10.7 million was the previous leader. Rhode Island's eight stores each generate more revenue than the average dispensary in any other state, not because the market is thriving but because it is catastrophically under-served.

The Metrc data for the 14-month period from January 2025 through February 2026 provides a detailed breakdown:

• $139.6 million total retail sales (14 months)
• $35.18 average transaction amount
• 6,842 active medical patients (February 2026)
• ~85% adult-use / 15% medical sales split

Product mix from the OCR public data dashboard tracks the national pattern almost exactly: pre-packaged flower dominates at 42% of retail spend ($50.9 million in 2025), followed by raw pre-rolls at 20% ($24.2 million), vape cartridges at 17% ($20.1 million), and edibles at 12% ($14.1 million). This distribution is virtually identical to mature markets like Colorado and Oregon, confirming that consumer preferences are consistent regardless of market stage or geography.

Rhode Island's flower price of $5.67 per gram comes directly from CCC Metrc transaction data — not menu scraping, not surveys, not estimates. This is the actual average retail price paid at the register for one gram of flower, calculated across every transaction in the seed-to-sale system.

At $5.67, Rhode Island sits in the mid-range — cheaper than every East Coast market except Massachusetts, and cheaper than its immediate neighbor Connecticut ($7.69). The tax rate isn't the problem — it's identical to Massachusetts'. The base price is, and that's a function of eight stores facing zero competition.

Total Addressable Market

Rhode Island's adult population 21+ is approximately 830,000. Applying the empirically validated consumption baseline of 18% participation at 1.0 gram per day:

• 149,400 estimated consumers
• 54.5 million grams annual demand (biologically fixed regardless of price)
• $309 million dollar TAM at current $5.67/g pricing

Against $120.1 million in 2025 retail sales:

A 39% capture rate from eight stores is actually respectable. For context:

Rhode Island's geography works in its favor — at ~1,034 square miles of land area, it's the smallest state in the country. Nobody is more than 30 minutes from a dispensary even with only eight locations. That geographic compression partially compensates for the extreme under-licensing, which is why the capture rate is higher than you'd expect for 0.96 stores per 100,000 adults.

But geography cuts both ways.

The Massachusetts Problem

Providence to the nearest Massachusetts dispensary in Seekonk or Attleboro is a 15-minute drive. Massachusetts flower retails at $4.01 per gram — and even after Massachusetts' ~20% tax stack, consumers pay roughly $4.81 out the door.

Rhode Island's $5.67 base price, after the state's tax burden, reaches $6.80 at the register: 10% state cannabis excise + 3% local option + 7% sales tax = approximately 20% effective rate, compounding.

That's a 40% price gap for crossing a state line that's functionally a highway exit. And the Massachusetts dispensaries know it. CommCan in Rehoboth markets itself as "located 15 minutes from both Providence and Fall River." Solar Cannabis describes its Seekonk location as "just a few miles from the Rhode Island border." These aren't dog whistles — they're billboards. Massachusetts dispensaries were literally running ads along the Rhode Island state border while Rhode Island's own retailers couldn't even advertise under the state's incomplete regulatory framework.

The infrastructure tells the same story. Massachusetts CCC licensing data shows 14 operational dispensaries in towns directly bordering Rhode Island — Fall River (6), Attleboro (3), Seekonk (2), Somerset (1), Rehoboth (1), and North Attleborough (1). That's nearly double Rhode Island's dispensary count, clustered in a strip of small towns whose local populations can't justify the density. Seekonk — population 16,000 — has two dispensaries, giving it a retail density of 12.5 per 100,000, nearly double the Massachusetts statewide average. You don't open two dispensaries in a town of 16,000 to serve Seekonk. You open them to serve Providence.

This is the same cross-border pattern documented in New Mexico, where Sunland Park (population 15,000) generates $62 million in annual cannabis sales — roughly 91% of which exceeds what local demand could produce — driven almost entirely by consumers crossing from prohibition-state Texas. Massachusetts doesn't report store-level sales data, so the dollar magnitude of Rhode Island's outflow is unverifiable. But the infrastructure signal is structurally identical: small border towns with outsized retail footprints that only make economic sense if the neighboring state's consumers are the actual customer base.

Providence City Council President Rachel Miller put it plainly in March 2026: "People are still just driving over the border to Massachusetts."

This is the inverse of the Montana and Maine dynamic. Those states exceed 100% legal capture because their neighbors are illegal — every border crossing flows in. Rhode Island's nearest neighbor is a mature market with 405 stores, lower prices, and no restrictions on out-of-state purchases. Border traffic flows out. Connecticut faces the same structural problem from the other side — squeezed between Massachusetts and New York — and manages only 20% capture.

The 39% capture rate, viewed through this lens, is not a measure of how much of the total market Rhode Island is serving. It's a measure of how much remains after Massachusetts takes its cut. The real competitor isn't the illicit market — it's the Massachusetts legal market.

The pattern is clear: final out-the-door price is the strongest predictor of legal capture. Every market under $5 final price achieves 100%+ capture. Every market over $8 final price is below 30%. Rhode Island's $6.80 lands in the uncomfortable middle — too expensive to dominate, cheap enough that the base price isn't the fundamental problem.

The Monopoly That Feeds Massachusetts

The 39% capture rate isn't just a tax problem. It's a regulatory capture problem.

Rhode Island has operated with 8 hybrid dispensaries since December 2022 — existing medical compassion centers that paid $125,000 for a hybrid license to sell adult-use cannabis. The Rhode Island Cannabis Act authorized 24 additional retail licenses, but the Cannabis Control Commission spent three years developing regulations before even opening applications in September 2025. During that delay, incumbents operated as a protected monopoly generating $15.0 million per store — the highest per-store revenue in the country.

Now that 24 new licenses are finally in the pipeline, the incumbents are lobbying to shrink the number. In March 2026, the CCC began considering issuing fewer than 24 licenses after existing dispensary operators raised concerns that new competition would hurt their profit margins. One incumbent owner argued the state "should not allow dispensaries on top of dispensaries on top of dispensaries" and suggested limiting new licenses to six to eight.

Meanwhile, Rhode Island's 60+ licensed cultivators are going bankrupt. With only 8 retail outlets to sell through, cultivators can't move product. "Sales have been really off and we were forced to lay off a lot of our staff," one cultivator told WPRI. "We're forced to slow down production." The bottleneck isn't supply — it's retail access, controlled by a handful of incumbents with no incentive to share shelf space with competitors.

The cultivator crisis runs deeper than simple retail access. Three of Rhode Island's original compassion centers are vertically integrated — they grow their own product. The six newer compassion centers are prohibited from cultivating, but the original three control significant retail volume with in-house supply. Outside cultivators are squeezed on wholesale pricing and shelf space, effectively subsidizing the incumbents' in-house brands. Cultivators have appeared at CCC meetings repeatedly to request fair shelf-space requirements, while the incumbents who control retail access have no incentive to stock competitors' products when they can push their own at higher margins. The worker-owned cooperative licenses included in the 24-store expansion were specifically designed to break this dynamic — cooperatives would be owned by their employees, not by vertically integrated operators with wholesale pricing power over independent cultivators.

The math is straightforward: 8 stores protecting $15.0 million each in annual revenue have a collective $120 million reason to block competition. Every new dispensary that opens dilutes their monopoly revenue. Every month the CCC delays is another month of $15.0 million per store. The cultivators absorb the losses. The consumers drive to Massachusetts. And Rhode Island's tax base shrinks.

Spencer Blier, CEO and founder of cultivator Mammoth Inc. in Warwick, told the commission directly: "The only people who stand to benefit from slow-rolling these dispensaries are the current dispensaries who have a monopoly on the cannabis market." Social equity applicant Ambrose Dwyer put it more bluntly: "They're scared of competition. They've got a monopoly, and they've got their prices through the roof."

The incumbents frame the expansion as a threat. Kevin Rouleau, COO of the Portsmouth-based Newport Cannabis Company, warned the commission that issuing all licenses at once could lead to a "race to the bottom" where "no one would profit by it." The Rhode Island Growers Association disagreed. "We're totally fine moving forward with retail stores and are not worried about that outcome," representative Nicholas Lacroix told the commission during public comment.

The data settles the debate. Rhode Island is currently capturing 39% of its addressable market. Sixty-one percent of consumer demand is going to Massachusetts dispensaries, the illicit market, or home cultivation. If new stores bring prices toward Massachusetts levels, the volume increase from recapturing cross-border consumers and converting illicit buyers dwarfs the per-unit margin compression. A market doing $120 million at $5.67/g with 39% capture would do over $200 million at $4.50/g with 65% capture. The "race to the bottom" argument only holds if you assume the market is already fully captured. It isn't even close.

The Tax Rate Isn't the Problem

Rhode Island's tax structure looks like this:

Massachusetts' effective tax rate is virtually identical: 10.75% excise + 6.25% sales + up to 3% local = ~20%. The two states tax cannabis at the same rate. The entire price gap between Rhode Island's $6.80 out the door and Massachusetts' $4.81 is driven by the base price: $5.67 versus $4.01. That's not a tax problem. That's a monopoly premium created by eight stores serving a market that needs 30+.

This reframes everything. Rhode Island doesn't need to cut taxes. It needs to issue the licenses the law already authorized. If competition from 32 stores drives the base flower price from $5.67 toward Massachusetts' $4.01, the math solves itself at the current 20% rate:

• At $4.50/g base: $5.40 out the door — within 12% of Massachusetts, close enough that convenience wins for most consumers
• At $4.01/g base (matching MA): $4.81 out the door — identical to Massachusetts. Zero incentive to cross the border.

The revenue implications are the opposite of what the incumbents claim. Rhode Island currently collects approximately $24 million in cannabis tax revenue ($120.1M × 20%). If density-driven competition compresses the base price to $4.50/g and capture rises from 39% to 65%:

• Volume TAM: 54.5 million grams (fixed — doesn't change with price)
• Dollar TAM at $4.50/g: $245 million
• 65% capture: $159 million in retail sales
• Tax at 20%: $31.8 million

That's $31.8 million versus today's $24 million — a 33% increase in tax revenue at the exact same tax rate, driven entirely by volume growth from higher capture. Lower prices, more stores, more revenue. The incumbents' "race to the bottom" is actually a race to a bigger tax base.

Even at full price convergence with Massachusetts ($4.01/g) and 80% capture, the state collects $29 million — still above today's $24 million. The tax rate doesn't need to be touched. The only thing standing between Rhode Island and higher cannabis tax revenue is the eight dispensaries lobbying to prevent competition.

Dispensary Density and the Coming Expansion

Projected row assumes 32 stores (8 existing + 24 authorized), price compression to $4.50/g from competitive density, and 65% capture — a conservative estimate. At $4.98M per store, Rhode Island's projected revenue per dispensary falls in line with Massachusetts ($4.07M) and Connecticut ($4.03M). The BMDE framework predicts higher capture at this price point and density.

Rhode Island's $15.0 million per store is an anomaly — 40% above Maryland's $10.7M and nearly four times the Massachusetts average. That number doesn't signal success; it signals a market where demand vastly exceeds licensed supply.

The CCC opened applications for 24 new adult-use retail licenses in September 2025, distributed across six geographic zones (four per zone). Applications closed December 29, 2025, with a lottery tentatively scheduled for May 2026. The licenses break down as: 12 open, 6 social equity, and 6 worker-owned cooperatives.

When (and if) all 24 new stores open, Rhode Island goes from 8 to 32 dispensaries:

• Density: 0.96 → 3.9 per 100,000 — comparable to Connecticut (2.5) and Maryland (2.3)
• Revenue per store (at current sales): $15.0M → $3.75M — still healthy, comparable to Massachusetts ($4.07M)
• Consumers per store: 18,675 → 4,669 — moving from catastrophic to merely tight

The geographic zone distribution should help reduce the Massachusetts bleed by placing dispensaries closer to consumers who currently cross the border. But density does more than add convenience — it's the mechanism that forces price compression. Every jurisdiction that achieved high capture rates did so through density first, with prices falling as a consequence of competition. No state has ever taxed or regulated its way to high capture without adequate store density. The lever is density. Price follows.

At 18,675 estimated consumers per store, Rhode Island is the second most under-served market in the country after Virginia. The 24 new licenses would drop this to 4,669.

The cross-jurisdictional pattern is unambiguous: no market below 2.0 stores per 100,000 adults has ever exceeded 40% legal capture. Every market above 7.0 per 100,000 has achieved full capture or better. Rhode Island at 0.96 per 100,000 is producing exactly the capture rate the density predicts — and there is no reason to believe capture will increase unless the density lever is pulled. More stores don't just add convenience. They create competition that compresses retail margins, drives down flower prices, and narrows the gap with Massachusetts. Density is the cause. Price compression is the effect. Capture is the outcome. Rhode Island is currently trying to achieve the outcome while the incumbents block the cause.

Home Cultivation

Adult-use (21+): Up to 6 plants per household (3 mature, 3 immature), regardless of number of adult residents. Must be grown at primary residence, indoors in a locked enclosed space, not visible to the public. No license or registration required. Landlord permission required for renters. Volatile solvent extraction (butane, etc.) is prohibited; non-solvent extracts and edibles are permitted.

Possession limits: 1 ounce in public, 10 ounces at home (max 5 grams concentrate). Gifting up to 1 ounce to another adult is legal.

Medical patients: Up to 12 mature + 12 immature plants, each requiring a valid plant tag certificate from the Office of Cannabis Regulation. Tags are issued in sets of two (one immature, one mature), valid for one year, at no cost since December 2022. Cooperative cultivation is permitted for two or more cardholders: up to 24 mature plants and 24 seedlings at residential locations, 48 mature and 48 seedlings at non-residential locations.

The 6-plant adult-use limit is standard for New England (Massachusetts and Connecticut have the same limit). The medical program's 12+12 with cooperative cultivation provisions is more generous than Hawaii's 10 plants with required grow site registration, creating a meaningful incentive for patients to maintain their medical cards despite the added cost and hassle of registration.

What the CHS Literature Missed

Rhode Island's 14-month Metrc dataset shows consistent, growing retail sales with no sign of mass consumer attrition. If cannabinoid hyperemesis syndrome affected 17-33% of daily users as some clinical literature claims, the state's approximately 26,900 daily consumers (18% of 149,400 estimated consumers) would include 4,573-8,877 CHS sufferers — a population that would produce measurable market contraction through reduced consumption or cessation. Instead, monthly sales have grown from $7.9 million in January 2025 to a peak of $10.7 million in August 2025. The behavioral falsification framework documents why high-prevalence CHS claims are mathematically incompatible with observed market behavior across all tracked jurisdictions.

The Bottom Line

Rhode Island is a $309 million cannabis market collecting $120 million through eight stores — a 39% capture rate suppressed by extreme under-licensing and regulatory capture by vertically integrated incumbents who have inflated the base price $1.66 above the Massachusetts equivalent while operating under an identical 20% tax rate.

The tax rate doesn't need to change. The density does. The 24 new licenses pending will break the monopoly pricing — if regulators resist incumbent pressure to reduce the number. More stores means competition. Competition means the base price compresses from $5.67 toward Massachusetts' $4.01. At $4.01/g, Rhode Island's out-the-door price matches Massachusetts exactly. The border bleed stops. Capture doubles. And the state collects $31+ million in tax revenue at the current rate — a 33% increase over today's $24 million.

Rhode Island has one advantage no other under-performing market shares: it's small enough that 32 stores genuinely covers the state. The question is whether regulators will issue the licenses the law authorized, or whether eight incumbents generating $15 million per store will continue dictating the pace of a market that exists to serve a million Rhode Islanders — not eight dispensary owners.

This analysis applies the Dan K Reports Cannabis Market Framework. For methodology, assumptions, and the complete state-by-state comparison, see the framework documentation.